IL152721A0 - Heterocyclic compounds and pharmaceutical compositions for inhibition of glycogen synthase kinase containing the same - Google Patents

Heterocyclic compounds and pharmaceutical compositions for inhibition of glycogen synthase kinase containing the same

Info

Publication number: IL152721A0
Authority: IL; Israel
Prior art keywords: inhibition; pharmaceutical compositions; same; heterocyclic compounds; glycogen synthase
Prior art date: 2000-05-11

Application number

IL15272101A

Other languages

English (en)

Original Assignee

Consejo Superior Investigacion

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-05-11

Filing date

2001-05-11

Publication date

2003-06-24

2000-05-11 Priority claimed from ES200001185A external-priority patent/ES2166328B1/es

2001-05-11 Application filed by Consejo Superior Investigacion filed Critical Consejo Superior Investigacion

2003-06-24 Publication of IL152721A0 publication Critical patent/IL152721A0/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
108091007911 GSKs Proteins 0.000 title 1
102000004103 Glycogen Synthase Kinases Human genes 0.000 title 1
150000002391 heterocyclic compounds Chemical class 0.000 title 1
230000005764 inhibitory process Effects 0.000 title 1
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010003210 Arteriosclerosis Diseases 0.000 abstract 1
102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 abstract 1
108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010054949 Metaplasia Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
201000004681 Psoriasis Diseases 0.000 abstract 1
208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000003463 hyperproliferative effect Effects 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
230000015689 metaplastic ossification Effects 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/13—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/385—Saturated compounds containing a keto group being part of a ring
- C07C49/395—Saturated compounds containing a keto group being part of a ring of a five-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
- C07C49/597—Unsaturated compounds containing a keto groups being part of a ring of a five-membered ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IL15272101A 2000-05-11 2001-05-11 Heterocyclic compounds and pharmaceutical compositions for inhibition of glycogen synthase kinase containing the same IL152721A0 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
ES200001185A ES2166328B1 (es)	2000-05-11	2000-05-11	Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
GB0030284A GB0030284D0 (en)	2000-05-11	2000-12-12	Enzyme inhibitors
PCT/GB2001/002100 WO2001085685A1 (en)	2000-05-11	2001-05-11	Heterocyclic inhibitors of glycogen synthase kinase gsk-3

Publications (1)

Publication Number	Publication Date
IL152721A0 true IL152721A0 (en)	2003-06-24

Family

ID=26156184

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL15272101A IL152721A0 (en)	2000-05-11	2001-05-11	Heterocyclic compounds and pharmaceutical compositions for inhibition of glycogen synthase kinase containing the same

Country Status (19)

Country	Link
US (3)	US6872737B2 (es)
EP (1)	EP1286964B1 (es)
KR (1)	KR100812407B1 (es)
CN (1)	CN100358867C (es)
AT (1)	ATE366238T1 (es)
AU (1)	AU783615B2 (es)
BR (1)	BR0110734A (es)
CA (1)	CA2408747C (es)
CY (1)	CY1106826T1 (es)
CZ (1)	CZ296087B6 (es)
DE (1)	DE60129222T2 (es)
DK (1)	DK1286964T3 (es)
ES (1)	ES2288948T3 (es)
HU (1)	HUP0302002A3 (es)
IL (1)	IL152721A0 (es)
MX (1)	MXPA02011079A (es)
PL (1)	PL209780B1 (es)
RU (1)	RU2294931C2 (es)
WO (1)	WO2001085685A1 (es)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2408747C (en) *	2000-05-11	2011-04-05	Consejo Superior Investigaciones Cientificas	Heterocyclic inhibitors of glycogen synthase kinase gsk-3
WO2003018011A1 (en) *	2001-08-24	2003-03-06	Wyeth Holdings Corporation	5-(substituted)-5-(substitutedsulfonyl or sulfanyl)thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
WO2003018554A1 (en)	2001-08-24	2003-03-06	Wyeth Holdings Corporation	3-substituted-3-(substitutedsulfonyl or sulfanyl)pyrrolidine-2,5-diones useful for inhibition of farnesyl-protein transferase
WO2004039412A2 (en) *	2002-10-29	2004-05-13	Engene, Inc.	Compositions for cancer treatment
GB0303319D0 (en)	2003-02-13	2003-03-19	Novartis Ag	Organic compounds
GB0327908D0 (en) *	2003-12-02	2004-01-07	Neuropharma Sa	GSK-3 inhibitors isolated from marine organisms
SE0303570L (sv) *	2003-12-03	2005-06-04	Microdrug Ag	Fukt-känslig medicinsk produkt
EP1574499A1 (en) *	2004-03-08	2005-09-14	DKFZ Deutsches Krebsforschungszentrum	Inhibitors of DNA methylation in tumor cells
EP1586318A1 (en) *	2004-04-05	2005-10-19	Neuropharma S.A.U.	Thiadiazolidinones as GSK-3 inhibitors
WO2006034207A2 (en) *	2004-09-17	2006-03-30	Vanderbilt University	Use of gsk3 inhibitors in combination with radiation therapies
WO2006045581A1 (en) *	2004-10-21	2006-05-04	Neuropharma, S.A.	The use of 1, 2, 4-thiadiazolidine-3, 5-diones as ppar activators
SE0500055D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 3
WO2006073364A1 (en) *	2005-01-10	2006-07-13	Astrazeneca Ab	Derivatives of isothiazol-3 (2h)-thione 1,1-dioxides as liver x receptor modulators
SE0500058D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 5
JP2008526841A (ja) *	2005-01-10	2008-07-24	アストラゼネカアクチボラグ	肝臓ｘ受容体調節因子としてのイソチアゾール−３（２ｈ）−オン１，１−ジオキシドのアニリン系誘導体
SE0500056D0 (sv) *	2005-01-10	2005-01-10	Astrazeneca Ab	Therapeutic agents 4
CA2599611C (en)	2005-02-09	2013-07-30	Chiang J. Li	Meleimide derivatives, pharmaceutical compositions and methods for treatment of cancer
ES2258406B1 (es) *	2005-02-10	2007-12-01	Neuropharma, S.A.	Uso de compuestos heterociclicos como agentes neurogenicos.
EP2258359A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis by muscarinic receptor modulation with sabcomelin
EP2275096A3 (en)	2005-08-26	2011-07-13	Braincells, Inc.	Neurogenesis via modulation of the muscarinic receptors
EP1940389A2 (en)	2005-10-21	2008-07-09	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
JP2009513672A (ja)	2005-10-31	2009-04-02	ブレインセルス，インコーポレイティド	神経発生のｇａｂａ受容体媒介調節
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
CA2651862A1 (en)	2006-05-09	2007-11-22	Braincells, Inc.	5 ht receptor mediated neurogenesis
EP2382975A3 (en)	2006-05-09	2012-02-29	Braincells, Inc.	Neurogenesis by modulating angiotensin
US8168667B2 (en)	2006-05-31	2012-05-01	Galapagos Nv	Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
CA2658263A1 (en) *	2006-07-18	2008-01-24	University Of Rochester	Thiadiazolidinone derivatives
KR20090064418A (ko)	2006-09-08	2009-06-18	브레인셀즈 인코퍼레이션	4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
WO2008057933A2 (en)	2006-11-02	2008-05-15	Aestus Therapeutics, Inc.	Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways
EP2392574B1 (en)	2007-06-22	2013-12-18	ArQule, Inc.	Indolyl pyrrolidines for the treatment of cancer
BRPI0813355A2 (pt)	2007-06-22	2014-12-30	Arqule Inc	Compostos de quinazolinona e métodos de uso dos mesmos
CA2690799C (en)	2007-06-22	2015-06-16	Arqule, Inc.	Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
US9029408B2 (en)	2008-06-16	2015-05-12	Gtx, Inc.	Compounds for treatment of cancer
LT3289876T (lt) *	2008-06-16	2022-11-10	University Of Tennessee Research Foundation	Junginiai, skirti vėžio gydymui
US9447049B2 (en)	2010-03-01	2016-09-20	University Of Tennessee Research Foundation	Compounds for treatment of cancer
GB2463514C (en)	2008-09-11	2018-09-26	Galapagos Nv	Imidazolidine compounds and uses therefor
WO2010099217A1 (en)	2009-02-25	2010-09-02	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
CN101519372B (zh) *	2009-04-01	2011-07-20	深圳市盛捷生物技术有限公司	用作GSK3抑制剂的苯并[e]异吲哚-1,3-二酮化合物及其制备
CN102596923B (zh)	2009-07-08	2015-04-29	波罗的海生物公司	1,2,4-噻唑烷-3-酮衍生物及其在癌症治疗中的用途
ITNA20090047A1 (it) *	2009-07-16	2011-01-17	Adele Bolognese	Agenti antitumorali con attività inibitoria di proteine di prenilazione, processo di preparazione e impieghi in campo medico
US8765920B2 (en)	2009-12-23	2014-07-01	The Scripps Research Institute	Tyrosine bioconjugation through aqueous Ene-like reactions
JP5879273B2 (ja)	2010-03-01	2016-03-08	ジーティーエックス・インコーポレイテッド	癌を処置するための化合物
WO2011151359A1 (en)	2010-06-02	2011-12-08	Noscira, S.A.	Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
US11068954B2 (en)	2015-11-20	2021-07-20	Voicemonk Inc	System for virtual agents to help customers and businesses
SG190957A1 (en)	2010-12-01	2013-07-31	Nissan Chemical Ind Ltd	Pyrazole compounds having therapeutic effect on multiple myeloma
US8865750B2 (en) *	2011-04-28	2014-10-21	The Regents Of The University Of Michigan	Small molecule inhibitors of RGS proteins
EP2527323A1 (en)	2011-05-24	2012-11-28	Noscira, S.A.	Urea carbonyl disulfide derivatives and their therapeutic uses
WO2013020024A2 (en) *	2011-08-03	2013-02-07	Karyopharm Therapeutics, Inc.	Maleimide compounds and methods of treatment
WO2013108026A1 (en)	2012-01-17	2013-07-25	Baltic Bio Ab	Thiadiazolone derivatives useful in the treatment of diabetes
LT2838888T (lt) *	2012-02-24	2017-08-10	Asd Therapeutics Partners Llc	Tiadiazolidindionai kaip gsk-3 inhibitoriai
CN103992312A (zh) *	2013-02-18	2014-08-20	江苏欧威医药有限公司	1,2,4-噻二唑-3,5-二酮衍生物及其药物组合物和应用
US9949961B2 (en) *	2013-03-14	2018-04-24	Rahimdzhan Roziev	Agent for the prophylaxis and/or treatment of neoplastic diseases
ES2786925T3 (es)	2013-03-14	2020-10-14	Brigham & Womens Hospital Inc	Composiciones y procedimientos para la expansión y el cultivo de células madre epiteliales
RU2522449C1 (ru) *	2013-03-14	2014-07-10	Общество с ограниченной ответственностью "Лечебное питание"	Средство, обладающее антипролиферативным и антиметастатическим действием, для лечения опухолевых заболеваний
US9795584B2 (en)	2013-07-30	2017-10-24	University Of South Florida	Treating an atypical protein kinase C enzyme abnormality
WO2015155738A2 (en)	2014-04-09	2015-10-15	Christopher Rudd	Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
KR20230019500A (ko)	2014-09-03	2023-02-08	더 브리검 앤드 우먼즈 하스피털, 인크.	청력 손실의 치료를 위해 내이 털세포를 생성하기 위한 조성물, 시스템, 및 방법
WO2016090355A2 (en) *	2014-12-05	2016-06-09	Massachusetts Institute Of Technology	Catechol-rich polymers from n-substituted maleimides
CA2978182A1 (en)	2015-03-17	2016-09-22	Regeneron Pharmaceuticals, Inc.	Amino acid acylation reagents and methods of using the same
EP3400286A1 (en)	2016-01-08	2018-11-14	Massachusetts Institute Of Technology	Production of differentiated enteroendocrine cells and insulin producing cells
US11260130B2 (en)	2016-03-02	2022-03-01	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10201540B2 (en)	2016-03-02	2019-02-12	Frequency Therapeutics, Inc.	Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10213511B2 (en)	2016-03-02	2019-02-26	Frequency Therapeutics, Inc.	Thermoreversible compositions for administration of therapeutic agents
JP7109446B2 (ja)	2016-12-30	2022-07-29	フリークエンシーセラピューティクスインコーポレイテッド	幹細胞／前駆支持細胞の自己複製を誘導するための１ｈ－ピロール－２，５－ジオン化合物およびその使用方法
RU2761429C2 (ru) *	2018-06-13	2021-12-08	Общество с ограниченной ответственностью "Тиацен"	Средство, обладающее противоопухолевым действием, для лечения онкологических заболеваний
US11617745B2 (en)	2018-08-17	2023-04-04	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by downregulating FOXO
CA3109647A1 (en)	2018-08-17	2020-02-20	Frequency Therapeutics, Inc.	Compositions and methods for generating hair cells by upregulating jag-1
WO2020163812A1 (en)	2019-02-08	2020-08-13	Frequency Therapeutics, Inc.	Valproic acid compounds and wnt agonists for treating ear disorders
CN110698380B (zh) *	2019-10-24	2021-01-15	华东理工大学	一种内酰胺衍生物及其制备方法与应用
CN116940356A (zh)	2021-02-11	2023-10-24	文卡研究公司	用于治疗致心律失常性心肌病的组合物和方法
EP4340832A1 (en)	2021-05-21	2024-03-27	Amo Pharma Ltd.	Method of treating rna repeat mediated diseases with rna repeat binding compound
EP4094760A1 (en)	2021-05-24	2022-11-30	Consejo Superior De Investigaciones Científicas	Thiadiazolidinones for their use in the treatment of limb-girdle muscular dystrophy
CN115197167B (zh) *	2022-07-22	2023-07-28	中国药科大学	1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2863803A (en) *	1957-05-13	1958-12-09	Stauffer Chemical Co	Protecting materials against fungi by applying substituted dithiono and thiono-oxo-thiadiazolidines
US3301894A (en)	1964-11-16	1967-01-31	Olin Mathieson	S-[nu'-(chlorocarbonyl)-amino] isothiocarbamyl chlorides and their preparation
DE1670701A1 (de)	1966-05-23	1970-11-12	Bayer Ag	Verfahren zur Darstellung von Thiaimidazolidinen
US3900485A (en)	1967-02-10	1975-08-19	Velsicol Chemical Corp	New substituted 1,2,4-thiadiazolidine-3,5-diones
US3534057A (en)	1968-05-28	1970-10-13	Velsicol Chemical Corp	Halogenation process for the production of certain oxadiazolidines and thiadiazolidines
DE2109755A1 (de)	1971-03-02	1972-09-07	Badische Anilin- & Soda-Fabrik Ag, 6700 Ludwigshafen	Substituierte Thiadiazolidindione
US4183816A (en) *	1978-11-01	1980-01-15	Olin Corporation	Use of 2,4-di(lower alkyl)-1,2,4-thiadiazolidin-3,5-diones as additives for functional fluids
JPS58216177A (ja)	1982-06-10	1983-12-15	Sumitomo Chem Co Ltd	フエニルチアジアゾリジンジオン誘導体、その製造法および該化合物を有効成分として含有する除草剤
ES2236702T3 (es) *	1993-12-23	2005-07-16	Eli Lilly And Company	Inhibidores de la proteina quinasa c.
JP3714685B2 (ja) *	1994-05-18	2005-11-09	第一サントリーファーマ株式会社	ハイメニアルディシン及びその誘導体並びにそれらの合成中間体の製造法並びにその合成中間体
DE4420522A1 (de) *	1994-06-13	1995-12-14	Bayer Ag	Bakterizide Thiadiazolidinone
ES2234300T3 (es) *	1998-10-08	2005-06-16	Smithkline Beecham Plc	3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
GB9828640D0 (en) *	1998-12-23	1999-02-17	Smithkline Beecham Plc	Novel method and compounds
GB9918180D0 (en) *	1999-08-02	1999-10-06	Smithkline Beecham Plc	Novel compositions
CA2408747C (en) *	2000-05-11	2011-04-05	Consejo Superior Investigaciones Cientificas	Heterocyclic inhibitors of glycogen synthase kinase gsk-3
GB0012056D0 (en) *	2000-05-18	2000-07-12	Consejo Superior Investigacion	Model for neurodegenerative disease
EP1586318A1 (en)	2004-04-05	2005-10-19	Neuropharma S.A.U.	Thiadiazolidinones as GSK-3 inhibitors

2001
- 2001-05-11 CA CA2408747A patent/CA2408747C/en not_active Expired - Lifetime
- 2001-05-11 AU AU54981/01A patent/AU783615B2/en not_active Ceased
- 2001-05-11 KR KR1020027015132A patent/KR100812407B1/ko not_active Expired - Fee Related
- 2001-05-11 AT AT01928117T patent/ATE366238T1/de active
- 2001-05-11 CN CNB01812738XA patent/CN100358867C/zh not_active Expired - Lifetime
- 2001-05-11 CZ CZ20023692A patent/CZ296087B6/cs not_active IP Right Cessation
- 2001-05-11 DK DK01928117T patent/DK1286964T3/da active
- 2001-05-11 BR BR0110734-8A patent/BR0110734A/pt not_active Application Discontinuation
- 2001-05-11 PL PL359671A patent/PL209780B1/pl unknown
- 2001-05-11 ES ES01928117T patent/ES2288948T3/es not_active Expired - Lifetime
- 2001-05-11 WO PCT/GB2001/002100 patent/WO2001085685A1/en not_active Ceased
- 2001-05-11 DE DE60129222T patent/DE60129222T2/de not_active Expired - Lifetime
- 2001-05-11 MX MXPA02011079A patent/MXPA02011079A/es active IP Right Grant
- 2001-05-11 HU HU0302002A patent/HUP0302002A3/hu unknown
- 2001-05-11 EP EP01928117A patent/EP1286964B1/en not_active Expired - Lifetime
- 2001-05-11 IL IL15272101A patent/IL152721A0/xx unknown
- 2001-05-11 RU RU2002133222/04A patent/RU2294931C2/ru not_active IP Right Cessation
2002
- 2002-11-08 US US10/290,569 patent/US6872737B2/en not_active Expired - Lifetime
2004
- 2004-08-12 US US10/917,175 patent/US7666885B2/en not_active Expired - Lifetime
2007
- 2007-04-20 US US11/788,755 patent/US7781463B2/en not_active Expired - Fee Related
- 2007-08-30 CY CY20071101111T patent/CY1106826T1/el unknown

Also Published As

Publication number	Publication date
CA2408747A1 (en)	2001-11-15
ATE366238T1 (de)	2007-07-15
US7666885B2 (en)	2010-02-23
MXPA02011079A (es)	2004-08-19
HUP0302002A2 (hu)	2003-09-29
DK1286964T3 (da)	2007-10-01
DE60129222D1 (de)	2007-08-16
CA2408747C (en)	2011-04-05
ES2288948T3 (es)	2008-02-01
KR100812407B1 (ko)	2008-03-11
CZ296087B6 (cs)	2006-01-11
US6872737B2 (en)	2005-03-29
US20030195238A1 (en)	2003-10-16
CY1106826T1 (el)	2012-05-23
BR0110734A (pt)	2003-02-04
PL359671A1 (en)	2004-09-06
US20080033012A1 (en)	2008-02-07
US20050014803A1 (en)	2005-01-20
CZ20023692A3 (cs)	2003-06-18
WO2001085685A1 (en)	2001-11-15
EP1286964B1 (en)	2007-07-04
PL209780B1 (pl)	2011-10-31
US7781463B2 (en)	2010-08-24
CN1568310A (zh)	2005-01-19
DE60129222T2 (de)	2008-03-06
KR20030025919A (ko)	2003-03-29
AU5498101A (en)	2001-11-20
CN100358867C (zh)	2008-01-02
EP1286964A1 (en)	2003-03-05
RU2294931C2 (ru)	2007-03-10
HUP0302002A3 (en)	2007-02-28
AU783615B2 (en)	2005-11-17

Publication	Publication Date	Title
IL152721A0 (en)	2003-06-24	Heterocyclic compounds and pharmaceutical compositions for inhibition of glycogen synthase kinase containing the same
IL151626A0 (en)	2003-04-10	Quinazoline compounds
CA2432132A1 (en)	2002-08-01	Pyrazole compounds useful as protein kinase inhibitors
MY146279A (en)	2012-07-31	Compounds affecting glucokinase
WO2002085909A8 (en)	2004-04-29	9-deazaguanine derivatives as inhibitors of gsk-3
NO20025792D0 (no)	2002-12-02	Kinazolinderivater for behandling av tumorer
MXPA03012004A (es)	2004-03-26	Derivados de aminonicotinato como moduladores de glucocinasa (glk).
GB0112348D0 (en)	2001-07-11	Compounds
WO2002022602A3 (en)	2002-06-27	Triazole compounds useful as protein kinase inhibitors
ATE268179T1 (de)	2004-06-15	Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung
IL171977A (en)	2010-12-30	Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
ATE344033T1 (de)	2006-11-15	Vinylphenyl-derivate als glk-aktivatoren
ATE316083T1 (de)	2006-02-15	Adamantanderivate
ATE358668T1 (de)	2007-04-15	Drogen zur behandlung maligner tumoren
WO2004026863A8 (en)	2005-04-21	Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
DE60229046D1 (de)	2008-11-06	Chinazolin derivate
TNSN05188A1 (en)	2007-06-11	4-aminopyrimidine-5-one
PL1727817T3 (pl)	2011-03-31	Pochodne azabicyklooktan-3-onu i ich zastosowanie
EP1291349A4 (en)	2003-08-27	MALTO-OLIGOSACCHARIDE DERIVATIVES AND USE THEREOF
WO2000078751A3 (en)	2001-03-08	Compounds for use in treatment of neurological disorders